CG Oncology

Update in progress

CGON (NasdaqGS)

CG Oncology, Inc. is a late-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer in the United States. It conducts multiple phase 2 and 3 trials of cretostimogene as monotherapy for high-risk non-muscle-invasive bladder cancer after BCG failure, including BOND-003, PIVOT-006, and CORE-008. Formerly Cold Genesys, it renamed in 2020 and is based in Irvine, California.